MAP plots funding route to US Levadex launch
This article was originally published in Scrip
MAP Pharmaceuticals appears optimistic about its chances of winning US FDA approval for Levadex (dihydroergotamine) after receiving a complete response letter (CRL) from the agency earlier this year, since the company has initiated a common stock offering to raise $52 million that it plans to spend on commercialising its inhaled migraine therapy.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.